Exagen Inc. (NASDAQ:XGN) Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP lowered its stake in Exagen Inc. (NASDAQ:XGN) by 35.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 490,205 shares of the company’s stock after selling 272,054 shares during the quarter. Wasatch Advisors LP owned about 2.82% of Exagen worth $1,515,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Palumbo Wealth Management LLC lifted its position in shares of Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after purchasing an additional 9,695 shares in the last quarter. Verus Capital Partners LLC acquired a new stake in shares of Exagen during the third quarter worth about $39,000. Creative Planning acquired a new stake in shares of Exagen during the third quarter worth about $110,000. Renaissance Technologies LLC lifted its position in shares of Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after purchasing an additional 45,476 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its position in shares of Exagen by 49.0% during the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Stock Up 3.4 %

XGN stock opened at $3.97 on Monday. The company’s 50 day moving average price is $3.00 and its 200 day moving average price is $2.56. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. Exagen Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $4.83.

Exagen (NASDAQ:XGN) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The firm had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. During the same period in the prior year, the firm earned ($0.31) earnings per share. As a group, analysts forecast that Exagen Inc. will post -0.87 EPS for the current year.

Insider Buying and Selling

In other Exagen news, major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $3.30, for a total transaction of $660,000.00. Following the sale, the insider now owns 2,108,958 shares of the company’s stock, valued at approximately $6,959,561.40. This trade represents a 8.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Aballi acquired 24,305 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were bought at an average cost of $2.81 per share, for a total transaction of $68,297.05. Following the acquisition, the chief executive officer now owns 689,799 shares of the company’s stock, valued at $1,938,335.19. This represents a 3.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 26.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, William Blair reissued an “outperform” rating on shares of Exagen in a research report on Wednesday, November 13th.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).